Tracker

ETF universe handoff

Opening ETF evidence benchSynchronizing prices, risk metrics, holdings coverage, and source lineage

Company context

Olympus Corp.

TSE:7733

Medical Specialties · benchmarked against Health Technology inside the JPJY constituent company universe.

Active tabFinancial reports

Current readWeak

Last close1,725.50

1M return-2.18%

Open symbol page Watchlist context

OverviewVerdict, thesis map, and valuation setup.FundamentalsDrivers, trajectory, and business quality.Financial reportsStatement tables, sorting, filtering, and acceleration.Ex-ante forecastTarget price, dividend yield, and total return by horizon.FactorsCompany factor exposure, rank, and universe context.Market viewMomentum, catalysts, charts, and symbol packet.AttributionLarge-move causes, residuals, and research backlog.OwnershipSEC 13F holder flow, crowding, and manager changes.PeersPeer heatmap and closest comparables.

Tab scope

Raw financial statements

Financial reports

Source and lookbackStored financial report rows12 report snapshots; latest report Jun 25, 2:12 AM GMT+8.

Sample and caveat28 reported metrics across 4 sections.Use this tab for its stated job; heavier model packets stay on their own tabs.

Traditional statement tables

Financial reports

12 reports · latest Jun 25, 2:12 AM GMT+8

Distinct report rows12

Sections4

Metrics28

Coverage100%

CompanyOlympus Corp.

Overview scoring

Fundamental overview

39/100 blended · 93/100 confidence · benchmark Closest peers

Blended fundamental score: Earnings 35/100; Cash flow 31/100; Balance sheet 44/100; Valuation 54/100.

Broad comparison

Cohort scorecard

Coverage-adjusted score with thinner cohorts automatically down-weighted

Cohort scorecard: Closest peers 39/100; Medical Specialties 51/100; Health Technology 38/100; JPJY constituent company universe 38/100.

Selected company rank

Rank and percentile

Confidence-adjusted standing inside each cohort

Rank and percentile: Closest peers #13 of 13; Medical Specialties #4 of 4; Health Technology #11 of 11; JPJY constituent company universe #154 of 168.

Section scoring matrix

Earnings, cash flow, balance sheet, and valuation

Heatmap score by cohort and statement section

Section scoring matrix: Closest peers Earnings 35/100; Cash flow 30/100; Balance sheet 42/100; Valuation 56/100.

Sort byFilter metrics

Specialist report review

Quant, PM, and risk-manager reads

Deterministic review lanes from stored report metrics

Quant review

Favorable acceleration6/21

Market cap has the largest second-order move at -109.72%. 6 metrics are accelerating favorably and 15 are decelerating.

Fundamental PM review

Growth and cash quality0/5

EPS TTM is 0.39 with -99.49% latest change. The PM lane checks revenue, EPS, cash flow, and margin confirmation together.

Risk manager review

Risk controls need review3 watch items

Debt / Equity is 0.38 with +22.49% latest change. The risk lane checks leverage, liquidity, and cash-yield deterioration.

Indexed report history

Financial report trend chart

First visible report = 100

Financial report trend chart: Total revenue 6.4B; Revenue quarter 1.9B; Operating income TTM 925.9M; Operating margin +14.55%.

Second order change

Acceleration chart

Favorable acceleration means the latest move improved versus the prior move

Acceleration chart: Total revenue -100.36%; Revenue quarter -104.62%; Operating income TTM -97.07%; Operating margin -3.23%.

PM / risk lens

Risk and quality radar

Directional score from change and acceleration

Risk and quality radar: Growth 13/100; Cash 28/100; Quality 27/100; Balance 49/100; Valuation 81/100.

Earnings

Metric trend table

10 of 10 metrics shown

Metric	Latest	Change	Acceleration	Trend	Samples
Total revenueRevenue	6.4B	-99.36%-981.1B	-100.36%-991B	decelerating	12
Revenue quarterRevenue	1.9B	-99.29%-259.2B	-104.62%-272.4B	decelerating	12
Revenue next quarterRevenue	1.4B	Need 2 reportsNeed 2 reports	Need 3 reportsNeed 3 reports	stable	1
Operating income TTMEarnings	925.9M	-99.40%-152.7B	-97.07%-149.1B	decelerating	12
Operating marginProfitability	+14.55%	-6.53%-1.02 pts	-3.23%-0.48 pts	decelerating	12
EPS TTMEarnings	0.39	-99.49%-74.96	-86.39%-63.61	decelerating	12
EPS next quarterEarnings	0.06	Need 2 reportsNeed 2 reports	Need 3 reportsNeed 3 reports	stable	1
Gross marginQuality	+64.72%	-2.29%-1.52 pts	-0.83%-0.54 pts	deteriorating	12
Net marginQuality	+6.75%	-21.45%-1.84 pts	-7.36%-0.43 pts	decelerating	12
Gross-to-net conversionQuality	+10.42%	-19.61%-2.54 pts	-6.79%-0.64 pts	decelerating	12

Historical statement rows

Earnings report history

12 dated rows

Snapshot date	Total revenue	Revenue quarter	Revenue next quarter	Operating income TTM	Operating margin	EPS TTM	EPS next quarter	Gross margin	Net margin	Gross-to-net conversion
Jul 3, 2023	897.4B	205B	—	175.1B	+19.51%	285.08	—	+67.79%	+13.75%	+20.29%
Oct 2, 2023	901.5B	226.6B	—	164.1B	+18.20%	232.50	—	+67.42%	+6.27%	+9.30%
Jan 4, 2024	916.1B	236.5B	—	159.2B	+17.38%	215.71	—	+67.08%	+4.31%	+6.42%
Apr 1, 2024	936.2B	257.7B	—	151.9B	+16.22%	193.94	—	+66.77%	+2.84%	+4.26%
Jul 1, 2024	963.3B	234.8B	—	160.8B	+16.69%	14.93	—	+66.86%	+2.90%	+4.34%
Oct 7, 2024	973.6B	239.2B	—	170.1B	+17.48%	64.34	—	+67.75%	+9.01%	+13.30%
Jan 6, 2025	985.7B	251.2B	—	169.3B	+17.18%	72.73	—	+67.43%	+9.72%	+14.42%
Apr 7, 2025	997.3B	272.1B	—	188B	+18.85%	102.94	—	+68.55%	+11.81%	+17.23%
Jul 7, 2025	969B	206.5B	—	163.6B	+16.88%	98.41	—	+68.38%	+11.56%	+16.90%
Oct 6, 2025	977.7B	247.8B	—	157.3B	+16.09%	86.70	—	+67.22%	+10.00%	+14.87%
Jan 5, 2026	987.5B	261B	—	153.7B	+15.56%	75.35	—	+66.24%	+8.59%	+12.96%
Jun 25, 2026	6.4B	1.9B	1.4B	925.9M	+14.55%	0.39	0.06	+64.72%	+6.75%	+10.42%